

cells have higher C3 concentration than MSC, as literature C3 elevated in endometrial cancer. Future work will explore the impact of other microbiome on C3 levels and downstream effects of endometrial cancer pathogenesis.

AS02. Breast cancer

EP024/#214

A RETROSPECTIVE ANALYSIS OF OUTCOMES OF MODIFIED HYPOFRACTIONATED BREAST RADIOTHERAPY FOR PATIENTS IN TYGERBERG HOSPITAL DURING THE 2020 CORONAVIRUS-19 PANDEMIC

Yashmeeta Bundhoo*. Tygerberg Hospital/Stellenbosch University, Medical Imaging and Clinical Oncology, Cape Town, South Africa

10.1136/ijgc-2023-IGCS.150

Introduction UK Standardization of Breast Radiotherapy (START) trials suggested that lower total doses of radiotherapy delivered in fewer fractions (40.05 Gy in 15 fractions) were as safe and effective as the historical 50 Gy in 25 fractions. The recent 26 Gy in 5 fractions regimen also compared favourably. The purpose was to retrospectively establish outcomes of a shorter hypofractionated schedule of adjuvant radiotherapy during COVID-19 pandemic for breast cancer patients at Tygerberg Hospital over one year (2020–2021), in terms of locoregional recurrence, distant metastasis, survival and side effects.

Methods This study was conducted as a retrospective chart review of breast cancer patients treated with radiotherapy at Tygerberg Hospital over the period of April to September 2020. Patients with stages I-IIIc invasive breast carcinoma scheduled for adjuvant radiotherapy were eligible.

Results Between 1st April and 30th September 2020, 161 patients were screened from Tygerberg Hospital breast multidisciplinary team meeting. 100 were eligible; 44 were assigned to 40.05 Gy in 15-day schedule and 56 to 26 Gy in 5-day fraction schedule. Over a median follow-up period of 15 months, it was reported that only four patients ($p = 0.206$, 95% CI; -0.316 – 0.71) got locoregional recurrence and ten developed metastases ($p = 0.691$ (95% CI, -0.235 – 0.157)). 16 patients passed away. No statistically significant difference was seen between schedules regarding side effect profile and survival analysis.

Conclusion/Implications 26 Gy in five fractions over one week was relatively equivalent to 40.05 Gy in fifteen fractions over three weeks for local tumour control and was as safe in terms of normal tissue effects up to 1 year for patients prescribed adjuvant breast radiotherapy after primary surgery.

EP025/#623

PROGNOSTIC VALUE OF TUMOR-INFILTRATING LYMPHOCYTE SCORE IN EARLY-STAGE TRIPLE-NEGATIVE BREAST CANCER: EXPERIENCE FROM A SINGLE CENTER IN VIETNAM

¹Hoai Hoang*, ²Huyen Phung, ³Ngoc Nguyen Tung, ⁴Thach Nguyen Dinh, ⁵Long Nguyen, ¹Thang Nguyen. ¹Hanoi Medical University, Department of Oncology, Hanoi, Viet Nam; ²Vietnam National Cancer Hospital (K hospital), No6 Medical Oncology Department, Hanoi, Viet Nam; ³Viet Duc hospital, Department of Pathology, Hanoi, Viet Nam; ⁴Vietnam National Cancer Hospital, Department of Pathology, Hanoi, Viet Nam; ⁵Vietnam National Cancer Hospital (K hospital), Medical Oncology Department No. 6, Hanoi, Viet Nam

10.1136/ijgc-2023-IGCS.151

Introduction To evaluate the prognostic value of tumor-infiltrating lymphocyte scores (TILs) and their correlation with clinicopathological features in patients with early-stage triple-negative breast cancer (TNBC) in Vietnam.

Abstract EP025/#623 Table 1 Correlation between TILs, CD8+ iTILs, CD8+ sTILs and clinicopathological features (n = 105)

Characteristic No. (%)	TILs (n=105)			CD8+ iTILs (n=105)			CD8+ sTILs (n=105)		
	Low	High	p value	Low	High	p value	Low	High	p value
Age, years, No. (%)									
≤ mean	9 (18.8)	5 (8.8)	0.13	9 (12.5)	5 (15.2)	0.46	10 (15.4)	4 (10)	0.32
> mean	39 (81.2)	52 (91.2)		63 (87.5)	28 (84.8)		55 (84.6)	36 (90)	
T stage, No. (%)									
1	19 (39.6)	31 (54.4)		35 (48.6)	15 (45.5)	0.77	25 (38.5)	25 (62.5)	
2	28 (58.3)	25 (43.9)	0.24	35 (48.6)	18 (54.5)		38 (58.5)	15 (37.5)	0.04*
3	1 (2.1)	1 (1.7)		2 (2.8)	0 (0)		2 (3.0)	0	
N status, No. (%)									
Negative	33 (68.8)	42 (73.7)	0.67	55 (76.4)	20 (60.6)	0.07	45 (69.2)	30 (75)	0.34
Positive	15 (31.2)	15 (26.3)		17 (23.6)	13 (39.4)		20 (30.8)	10 (25)	
Tumor grade, No. (%)									
1,2	24 (50)	20 (35.1)	0.12	33 (45.8)	11 (33.3)	0.16	31 (47.7)	13 (32.5)	0.09
3	24 (50)	37 (64.9)		39 (54.2)	22 (66.7)		34 (45.3)	27 (67.5)	
Local treatment, No. (%)									
BCS	1 (2.1)	2 (3.5)	0.56	3 (4.2)	0 (0)	0.32	1 (1.5)	2 (5.0)	0.32
Mastectomy	47 (97.9)	55 (96.5)		69 (95.8)	33 (100)		64 (98.5)	38 (95.0)	
Ki67, No. (%)									
<20	7 (14.9)	3 (5.6)	0.09	8 (11.2)	2 (6.1)		8 (12.5)	2 (5.0)	0.18
≥ 20	40 (85.1)	54 (94.7)		63 (88.7)	31 (93.9)		56 (88.5)	38 (95.0)	
Lymphovascular invasion									
No. (%)									
Absent	45 (93.8)	56 (98.2)	0.24	69 (95.8)	32 (97.0)	0.62	61 (93.8)	40 (100)	0.14
Present	3 (6.2)	1 (1.8)		3 (4.2)	1 (3.0)		4 (6.2)	0 (0)	
Her2 status, No. (%)									
Negative	40 (83.3)	55 (96.5)	0.02*	64 (88.9)	31 (93.9)	0.34	57 (87.7)	38 (95.0)	0.18
Her2-low	8 (16.7)	2 (3.5)		8 (11.1)	2 (6.1)		8 (12.3)	2 (5.0)	

(Pearson's Chi squared test or Fisher's exact test using median TIL value as the cut-off)